CELATOR PHARMACEUTICALS, INC.;OREGON HEALTH & SCIENCE UNIVERSITY; INC.;CELATOR PHARMACEUTICALS
发明人:
GORDON, MAX,TARDI, PAUL,TYNER, JEFFREY,MAYER, LAWRENCE
申请号：
CA3005076
公开号：
CA3005076A1
申请日:
2016.11.10
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
